메뉴 건너뛰기




Volumn 70, Issue 1-2, 2013, Pages 35-41

Swiss analysis of multiple sclerosis: A multicenter, non-interventional, retrospective cohort study of disease-modifying therapies

Author keywords

Disease modifying therapies; Efficacy; Multiple sclerosis; Safety; Swiss Analysis of Multiple Sclerosis study

Indexed keywords

BETA1A INTERFERON; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLATIRAMER; INTERFERON BETA SERINE;

EID: 84883191581     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000346761     Document Type: Article
Times cited : (9)

References (26)
  • 1
    • 0027418515 scopus 로고
    • Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo- controlled trial
    • IFNB Multiple Sclerosis Study Group
    • IFNB Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo- controlled trial. Neurology 1993 43 655-661.
    • (1993) Neurology , vol.43 , pp. 655-661
  • 3
    • 0029082566 scopus 로고
    • Copolymer 1 reduces relapse rate and improves disability in relapsing- remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebocontrolled trial
    • The Copolymer 1 Multiple Sclerosis Study Group
    • Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB: Copolymer 1 reduces relapse rate and improves disability in relapsing- remitting multiple sclerosis: results of a phase III multicenter, double-blind placebocontrolled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45: 1268-1276.
    • (1995) Neurology , vol.45 , pp. 1268-1276
    • Johnson, K.P.1    Brooks, B.R.2    Cohen, J.A.3    Ford, C.C.4    Goldstein, J.5    Lisak, R.P.6    Myers, L.W.7    Panitch, H.S.8    Rose, J.W.9    Schiffer, R.B.10
  • 4
    • 0345601517 scopus 로고    scopus 로고
    • Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis
    • PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group
    • PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
    • (1998) Lancet , vol.352 , pp. 1498-1504
  • 5
    • 0027521002 scopus 로고
    • Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial
    • UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group
    • Paty DW, Li DK: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993; 43: 662-667.
    • (1993) Neurology , vol.43 , pp. 662-667
    • Paty, D.W.1    Li, D.K.2
  • 6
    • 0035091667 scopus 로고    scopus 로고
    • European/ Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging - Measured disease activity and burden in patients with relapsing multiple sclerosis
    • European/Canadian Glatiramer Acetate Study Group
    • Comi G, Filippi M, Wolinsky JS: European/ Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging - measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001; 49: 290-297.
    • (2001) Ann Neurol , vol.49 , pp. 290-297
    • Comi, G.1    Filippi, M.2    Wolinsky, J.S.3
  • 8
    • 51449101000 scopus 로고    scopus 로고
    • Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): A multicentre, randomised, parallel, open-label trial
    • REGARD study Group
    • Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag BM, REGARD study Group: Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008; 7: 903-914.
    • (2008) Lancet Neurol , vol.7 , pp. 903-914
    • Mikol, D.D.1    Barkhof, F.2    Chang, P.3    Coyle, P.K.4    Jeffery, D.R.5    Schwid, S.R.6    Stubinski, B.7    Uitdehaag, B.M.8
  • 9
    • 0037180479 scopus 로고    scopus 로고
    • Randomized, comparative study of interferon ?-1a treatment regimens in MS: The EVIDENCE Trial
    • EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group University of British Columbia MS/ MRI Research Group
    • Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, OConnor P, Monaghan E, Li D, Weinshenker B, EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group, University of British Columbia MS/ MRI Research Group: Randomized, comparative study of interferon ?-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002; 59: 1496-506.
    • (2002) Neurology , vol.59 , pp. 1496-1506
    • Panitch, H.1    Goodin, D.S.2    Francis, G.3    Chang, P.4    Coyle, P.K.5    Oconnor, P.6    Monaghan, E.7    Li, D.8    Weinshenker, B.9
  • 10
    • 0037181634 scopus 로고    scopus 로고
    • Every-other-day interferon beta-1b versus once-weekly interferon beta- 1a for multiple sclerosis: Results of a 2-year prospective randomised multicentre study (INCOMIN)
    • INCOMIN Trial Study Group
    • Durelli L, Verdun E, Barbero P, Ricci A, Zhong JJ, Ferrero B, Clerico M, Pipieri A, Verdun E, Giordano L, Durelli L, INCOMIN Trial Study Group: Every-other-day interferon beta-1b versus once-weekly interferon beta- 1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453-1460.
    • (2002) Lancet , vol.359 , pp. 1453-1460
    • Durelli, L.1    Verdun, E.2    Barbero, P.3    Ricci, A.4    Zhong, J.J.5    Ferrero, B.6    Clerico, M.7    Pipieri, A.8    Verdun, E.9    Giordano, L.10    Durelli, L.11
  • 11
    • 0348012903 scopus 로고    scopus 로고
    • A post-marketing study on interferon beta 1b and 1a treatment in relapsingremitting multiple sclerosis: Different response in drop-outs and treated patients
    • North Italy Multiple Sclerosis Group
    • Milanese C, La Mantia L, Palumbo R, Martinelli V, Murialdo A, Zaffaroni M, Caputo D, Capra R, Bergamaschi R, North Italy Multiple Sclerosis Group: A post-marketing study on interferon beta 1b and 1a treatment in relapsingremitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 2003; 74: 1689-1692.
    • (2003) J Neurol Neurosurg Psychiatry , vol.74 , pp. 1689-1692
    • Milanese, C.1    La Mantia, L.2    Palumbo, R.3    Martinelli, V.4    Murialdo, A.5    Zaffaroni, M.6    Caputo, D.7    Capra, R.8    Bergamaschi, R.9
  • 12
    • 10344244660 scopus 로고    scopus 로고
    • Comparative clinical efficacy analysis between interferon beta 1-b and interferon beta 1-a (abstract)
    • Miralles AA, Fuentes B, Barreiro P, Diez- Tejedor E: Comparative clinical efficacy analysis between interferon beta 1-b and interferon beta 1-a (abstract). J Neurol 2000; 247:III139.
    • (2000) J Neurol , vol.247
    • Miralles, A.A.1    Fuentes, B.2    Barreiro, P.3    Diez- Tejedor, E.4
  • 13
    • 0013304348 scopus 로고    scopus 로고
    • An open-label trial comparing the effects of IFN?-1a (Rebif), (Avonex), and IFN?-1b (Betaferon) on the relapse rate, lesion load on MRI and disease progression in patients with relapsing-remitting multiple sclerosis: Results of 24 months of therapy (abstract P312)
    • Oztekin N, Oztekin MF: An open-label trial comparing the effects of IFN?-1a (Rebif), (Avonex), and IFN?-1b (Betaferon) on the relapse rate, lesion load on MRI and disease progression in patients with relapsing-remitting multiple sclerosis: results of 24 months of therapy (abstract P312). Mult Scler 2001; 7(suppl 1):S96.
    • (2001) Mult Scler , vol.7 , Issue.SUPPL. 1
    • Oztekin, N.1    Oztekin, M.F.2
  • 14
    • 0013272418 scopus 로고    scopus 로고
    • Response to beta-interferon in Iranian multiple sclerosis patients (abstract P146)
    • Pakdaman H: Response to beta-interferon in Iranian multiple sclerosis patients (abstract P146). Mult Scler 2001; 7(suppl 1):S54.
    • (2001) Mult Scler , vol.7 , Issue.SUPPL. 1
    • Pakdaman, H.1
  • 15
    • 22144447781 scopus 로고    scopus 로고
    • Interferon beta in relapsingremitting multiple sclerosis: An eight years experience in a specialist multiple sclerosis centre
    • Rio J, Tintore M, Nos C, Tellez N, Galan I, Montalban X: Interferon beta in relapsingremitting multiple sclerosis: an eight years experience in a specialist multiple sclerosis centre. J Neurol 2005; 252: 795-800.
    • (2005) J Neurol , vol.252 , pp. 795-800
    • Rio, J.1    Tintore, M.2    Nos, C.3    Tellez, N.4    Galan, I.5    Montalban, X.6
  • 16
    • 0013261347 scopus 로고    scopus 로고
    • Experience of interferon beta (INF-?) treatment in relapsing-remitting (RR) and secondary progressive (SP) multiple sclerosis (MS) in Galicia (Spain) (abstract P144)
    • Seijo-Martinez M, Amigo MC, Arias M, et al: Experience of interferon beta (INF-?) treatment in relapsing-remitting (RR) and secondary progressive (SP) multiple sclerosis (MS) in Galicia (Spain) (abstract P144). Mult Scler 2001; 7(suppl 1):S54.
    • (2001) Mult Scler , vol.7 , Issue.SUPPL. 1
    • Seijo-Martinez, M.1    Amigo, M.C.2    Arias, M.3
  • 18
    • 33644905869 scopus 로고    scopus 로고
    • Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study
    • Patti F, Pappalardo A, Florio C, Politi G, Fiorilla T, Reggio E, Reggio A: Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study. Acta Neurol Scand 2006; 113: 241-247.
    • (2006) Acta Neurol Scand , vol.113 , pp. 241-247
    • Patti, F.1    Pappalardo, A.2    Florio, C.3    Politi, G.4    Fiorilla, T.5    Reggio, E.6    Reggio, A.7
  • 20
    • 0035211356 scopus 로고    scopus 로고
    • A prospective, openlabel treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis: Results after 18 months of therapy
    • Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP: A prospective, openlabel treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy. Mult Scler 2001; 7: 349-353.
    • (2001) Mult Scler , vol.7 , pp. 349-353
    • Khan, O.A.1    Tselis, A.C.2    Kamholz, J.A.3    Garbern, J.Y.4    Lewis, R.A.5    Lisak, R.P.6
  • 21
    • 20044388168 scopus 로고    scopus 로고
    • Twenty-four-month comparison of immunomodulatory treatments - A retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone)
    • Haas J, Firzlaff M: Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). Eur J Neurol 2005; 12: 425-431.
    • (2005) Eur J Neurol , vol.12 , pp. 425-431
    • Haas, J.1    Firzlaff, M.2
  • 24
    • 79953017502 scopus 로고    scopus 로고
    • Current disease-modifying treatment of multiple sclerosis
    • Derwenskus J: Current disease-modifying treatment of multiple sclerosis. Mt Sinai J Med 2011; 78: 161-175.
    • (2011) Mt Sinai J Med , vol.78 , pp. 161-175
    • Derwenskus, J.1
  • 25
    • 0037161296 scopus 로고    scopus 로고
    • Randomized controlled trials to assess therapies for multiple sclerosis
    • Wingerchuk DM, Noseworthy JH: Randomized controlled trials to assess therapies for multiple sclerosis. Neurology 2002; 58(suppl 4):S40-S48.
    • (2002) Neurology , vol.58 , Issue.SUPPL. 4
    • Wingerchuk, D.M.1    Noseworthy, J.H.2
  • 26
    • 0034702233 scopus 로고    scopus 로고
    • A comparison of observational studies and randomized, controlled trials
    • Benson K, Hartz AJ: A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342: 1878-1886.
    • (2000) N Engl J Med , vol.342 , pp. 1878-1886
    • Benson, K.1    Hartz, A.J.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.